SUBSCRIBE Blog with us: BLOGbiotech

Breaking News

• Email
• Print
• Share
• More News

Jan 8 2007, 11:00 AM EST

Cubist Pharmaceuticals Announces Fourth Quarter 2006 U.S. Net Product Revenues of $56.2 Million and Full Year 2006 U.S. Net Product Revenues of $189.5 Million

News source: Business Wire

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported U.S. net product revenues of $56.2 million (unaudited) for the fourth quarter of 2006 for its antibiotic product CUBICIN(R) (daptomycin for injection). This result represents an increase of 54%, or $19.6 million, from fourth quarter 2005 U.S. net product revenues. Full year 2006 U.S. net product revenues were $189.5 million (unaudited).

Mike Bonney, President and CEO of Cubist said, "CUBICIN has experienced year-over-year growth of 67% in the U.S. in its third full year as an acute care antibiotic. Hundreds of thousands of patients with serious infections have now benefited from treatment with this important therapy. I am particularly pleased with the acceleration in growth in CUBICIN's average daily net product sales in the U.S.- $907,000 in Q4, an uptick of more than 15% vs. Q3. This is an increase of $121,000 -- the largest quarter-over-quarter growth in average daily sales since launch. Our commercial organization is continuing to make inroads in educating acute care physicians about the label expansion for S. aureus bloodstream infections approved by the FDA in late May."

Cubist will issue its full earnings release and host its fourth quarter and full year 2006 earnings conference call and webcast with slides on Wednesday, January 24th. The webcast presentation will also include a discussion of the company's business activities, financial outlook, and current news. Details are provided below.

   *************CONFERENCE CALL & WEBCAST INFORMATION*************

Cubist will host a conference call and live audio webcast to discuss
  its fourth quarter and full year 2006 financial results, business
                   activities and financial outlook.

          WHEN: Wednesday, January 24, 2007 at 5:00 p.m. ET

             LIVE DOMESTIC & CANADA CALL-IN: 877-407-0778

               LIVE INTERNATIONAL CALL-IN: 201-689-8565

            24-HOUR REPLAY DOMESTIC & CANADA: 877-660-6853

              24-HOUR REPLAY INTERNATIONAL: 201-612-7415

            REPLAY PASSCODES (BOTH REQUIRED FOR PLAYBACK):

                            ACCOUNT #: 286

                       CONFERENCE ID #: 225163

   CALL WILL ALSO BE BROADCAST LIVE, LISTEN ONLY, VIA THE WEB AT:
                            www.cubist.com

        Replay will be available for 30 days via the Internet
  ******************************************************************

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides. The Cubist product pipeline includes our lipopeptide program and our natural products screening program. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.

Cubist Safe Harbor Statement

Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and such statements are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cubist. These factors include, but are not limited to: (i) whether we will receive, and the potential timing and scope of, regulatory approvals or clearances to market CUBICIN in other countries pursuant to our currently planned filings and any filings we determine to make in the future, which filings are subject to appro

• Email
• Print
• Share
• More News

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR